-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shisi Pharmaceutical Group Delivers an Outstanding Interim Report
Category:
发布时间：2021-08-27
【概要描述】
Facing the severe and ongoing challenges posed by the normalization of COVID-19 both domestically and internationally, Shisi Pharmaceutical Group adopted a multi-pronged approach in the first half of this year to drive innovation and safeguard market performance. The company advanced the entire industrial chain—from pharmaceutical packaging materials and active pharmaceutical ingredients to high-end formulations—while promoting synergistic integration across diverse dosage forms. As a result, new products and products that have passed evaluation were approved one after another, further expanding the company’s market advantages. In doing so, Shisi Pharmaceutical effectively countered the various adverse impacts brought on by the pandemic and delivered an outstanding performance: the interim report shows that sales revenue increased by 37% year on year, net profit rose by 11.6% year on year, and the company once again ranked among China’s Top 100 Pharmaceutical Manufacturers and the Top 30 Best Pharmaceutical R&D Companies in China.
In the first half of the year, Shisi Pharmaceutical Group focused its core business efforts on market-enhancement initiatives centered on market access, product mix optimization, segment-specific refinement, and the launch of distinctive new products, while proactively implementing measures to drive breakthroughs in the market share of both finished dosage forms and active pharmaceutical ingredients.
Taking national centralized procurement and provincial- and regional volume-based procurement as opportunities, the Group is continuously expanding the market accessibility of its products. In the first half of the year, four products—ambroxol hydrochloride injection, doxofylline injection, fluconazole sodium chloride injection, and ropivacaine hydrochloride injection—covering six specifications, were selected in the fourth and fifth rounds of national drug centralized procurement. To date, Shisi Pharmaceutical Group has secured inclusion in national drug centralized procurement for six products across nine specifications, thereby creating favorable conditions for accelerating the transition of new product development from regional-market penetration to coordinated nationwide market expansion.
New products have delivered outstanding performance, with the ampoule product line in particular emerging as a key growth driver for the company’s injectable pharmaceutical segment. While ampoule formulations such as Betahistine Hydrochloride Injection, Bromhexine Hydrochloride Injection, and Terbutaline Sulfate Solution for Nebulization have accelerated their market expansion, three additional products—Ambroxol Hydrochloride Injection, Doxofylline Injection, and Ropivacaine Hydrochloride Injection—have successively been included in the National Centralized Procurement Program, serving as new pivotal levers for the group’s ampoule portfolio to achieve rapid scale-up and breakthroughs. In the first half of the year, sales of ampoule products reached RMB 406.49 million, representing a 53% increase and sustaining strong growth momentum.
The API business continues to gain momentum, with ongoing optimization and upgrading of production processes, as well as the renovation and enhancement of environmental protection and treatment capabilities, leading to a rapid expansion of production capacity. Bulk APIs are now exported extensively to markets in South America, Europe, Asia, and beyond, while the industrialization of specialty APIs such as lurasidone hydrochloride, linezolid, and terbutaline sulfate is accelerating, thereby becoming a key driver of the Group’s growth potential.
The supporting capabilities of pharmaceutical packaging materials within the industrial chain continue to strengthen. A multilayer co-extruded biopharmaceutical-grade film for single-use fluid-handling systems, which meets both USP Class VI requirements and relevant national standards, has now entered industrial-scale production. This product is widely used in the research, development, and manufacturing of vaccines and biopharmaceuticals, making the company the only domestic manufacturer currently capable of replacing imported biopharmaceutical films, with promising market prospects.
Innovation intensity and sophistication are steadily increasing, and the product portfolio is becoming increasingly diverse, providing a powerful engine for the company’s high-quality development. Building on collaborations with numerous “Double First-Class” universities and research institutions, the company entered into a strategic cooperation agreement with China Pharmaceutical University in June of this year. Through the establishment of an integrated industry–academia–research platform for new-drug R&D, the partnership aims to foster technological innovation and accelerate the commercialization of scientific and technological achievements.
In light of both the current and potential market landscape, Shisi Pharmaceutical Group remains steadfast in advancing the research and development of innovative drugs and generic medications, as well as conducting consistency evaluation studies for generics. Its first innovative drug—Class 1 new drug NP-01—has entered Phase I clinical trials, while other innovative candidates, such as Class 1 anti-liver-fibrosis drug AND-9, are accelerating their preclinical development. Notable progress has been made in consistency-evaluation projects, with a total of 15 drug varieties encompassing 20 dosage forms now having either passed or being deemed to have passed the consistency evaluation. In the first half of the year, the company secured a total of seven production approvals. To date, Shisi Pharmaceutical Group has submitted applications for a cumulative total of 61 new-product projects, including 35 liquid and solid dosage-form products, 13 consistency-evaluation products, and 13 active pharmaceutical ingredients. These sustained efforts in innovation are steadily yielding results, building up substantial momentum to drive the transformation and expansion of the group’s sales and production mix.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091